
Manifold
Financial History
Manifold has raised $31.0M across 2 funding rounds.
Leadership Team
Key people at Manifold.
Frequently Asked Questions
How much funding has Manifold raised?
Manifold has raised $31.0M in total across 2 funding rounds.

Manifold has raised $31.0M across 2 funding rounds.
Key people at Manifold.
Manifold has raised $31.0M in total across 2 funding rounds.
Manifold has raised $31.0M in total across 2 funding rounds.
Manifold's investors include Accel, Avalancha Ventures, Benchmark, Buckley Ventures, Cowboy Ventures, E14 Fund, Felix Capital, Floodgate, Founders Fund, Human Augmentation Syndicate, Long Journey Ventures, March Capital.
Manifold is an AI-powered clinical and life sciences research platform that accelerates biomedical R&D by automating the data-heavy, manual workflows that slow down modern research. The company builds a secure, scalable infrastructure that streamlines data collection, harmonization, governance, and analysis—turning what used to take months into insights generated in minutes. Its platform is designed specifically for complex, data-intensive research environments like cancer centers, population cohort studies, and omics-driven discovery.
Manifold serves leading academic medical centers, comprehensive cancer centers, and large-scale research organizations that struggle with fragmented data, legacy tools (like spreadsheets), and inefficient collaboration. It solves the systemic problem of brilliant scientists spending more time wrangling data than doing science. With $15 million in Series A funding in 2024 and a strategic collaboration with the Broad Institute of MIT and Harvard in early 2025, Manifold is gaining strong momentum as a next-generation research infrastructure provider in digital health and AI-driven life sciences.
---
Manifold was founded in 2016 in Newton, Massachusetts by four friends—Sourav Dey, Vivek Mohta, Rajendra Koppula, and Vinay Seth Mohta—as an AI lab focused on helping life sciences organizations move AI R&D projects into production. The founders, all with deep technical and AI/ML backgrounds, repeatedly observed a common pattern: world-class scientists were drowning in data complexity, forced to act like software engineers instead of biologists or clinicians. The problem wasn’t a lack of data or talent—it was the absence of a robust, intuitive data and AI foundation tailored to biomedical research.
This insight led to a pivotal shift in 2022: rather than building bespoke AI solutions for each client, the team decided to build a unified AI-powered research platform from the ground up. That platform became Manifold’s core product—an infrastructure layer that abstracts away the technical complexity of data pipelines, cohort building, and analysis so researchers can focus on discovery. Vinay Seth Mohta, who previously co-founded and served as CTO of Kyruus Health (a leading enterprise care access platform), brought operational and product leadership to scale this vision into a company trusted by top-tier research institutions.
---
---
Manifold sits at the intersection of three powerful trends: the explosion of biomedical data, the maturation of AI/ML in life sciences, and the urgent need to modernize research infrastructure. As omics, real-world data, and digital biomarkers become central to drug discovery and precision medicine, traditional tools like Excel and custom scripts are no longer tenable. At the same time, AI is unlocking new possibilities in target discovery, patient stratification, and trial design—but only if researchers can access and analyze data quickly and securely.
The timing is critical: research organizations are under pressure to do more with constrained budgets, while regulators and funders increasingly demand reproducibility, transparency, and scalability. Manifold addresses this by providing a standardized, AI-powered “operating system” for research that reduces cost, accelerates timelines, and improves data quality. By lowering the technical barrier to advanced analytics, it also democratizes access to cutting-edge methods, enabling more institutions—especially those without large engineering teams—to participate in high-impact science.
In the broader ecosystem, Manifold is helping to redefine what’s possible in clinical and translational research. Its collaboration with the Broad Institute signals a shift toward open, interoperable, cloud-native platforms that support global collaboration and secure data sharing. This positions Manifold not just as a software vendor, but as a key enabler of the next generation of biomedical discovery.
---
Manifold is poised to become a foundational layer in modern life sciences R&D, much like Snowflake or Databricks in enterprise data, but tailored specifically for the unique demands of biomedical research. Its bold vision—to make research ten times faster and one-tenth the cost—is ambitious, but its early traction with elite institutions and its deep technical pedigree suggest it’s on a credible path.
Looking ahead, Manifold will likely expand its footprint across academic medical centers, pharma R&D, and large population health initiatives. As AI models become more sophisticated and multimodal (e.g., combining genomics, imaging, and EHR data), the value of a unified, AI-native data platform will only grow. The company may also move further up the stack, offering pre-built AI workflows, trial design assistants, or even decision-support tools for clinical research operations.
In a world where breakthroughs in cancer, neurodegeneration, and precision medicine depend on how fast and well we can learn from data, Manifold’s mission—to free scientists from data drudgery and let them focus on discovery—could have an outsized impact on the future of medicine.
Key people at Manifold.
Manifold has raised $31.0M across 2 funding rounds. Most recently, it raised $15.0M Series A in November 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2023 | $15.0M Series A | Accel, Avalancha Ventures, Benchmark, Buckley Ventures, Cowboy Ventures, E14 Fund, Felix Capital, Floodgate, Founders Fund, Human Augmentation Syndicate, Long Journey Ventures, March Capital, Mayfield, Nyca Partners, QueensBridge Venture Partners, Rainfall Ventures, Relay Ventures, Seven Seven Six, Signia Venture Partners, Howard Lindzon, Susa Ventures, Talis Capital, Greg Bettinelli, The Hit Forge, Tiger Global Management, TQ Ventures, Transmedia Capital, Y Combinator, Aleksander Leonard Larsen, Cato Sælid, Eric Ries, Eugene Wei, John Fontein, Josh Spear, Julius Genachowski, Kevin Lin, Michael Birch, Nico Rosberg, Sahin Boydas, Sean Park, Xen Lategan | |
| Dec 1, 2022 | $16.0M Seed | Artichoke Capital, Delta Blockchain Fund, Polygon, Gil Penchina, Eddie Lou, Stani Kulechov |